@article{bibcite_3386,
  author = {Evangelos P Daskalopoulos and Pierre Deceuninck and Maurice Whelan and Laura Gribaldo},
  title = {Transition to innovative, human-relevant pre-clinical cardiovascular research: a perspective},
  abstract = {Cardiovascular diseases (CVDs) remain the leading cause of mortality and morbidity worldwide. It is estimated that approximately 17.9 million people died from CVDs in 2019, which represented 32\% of all deaths globally. Coronary heart disease is the commonest type of CVDs, contributing to the death of more than 380 000 people in 2020 in the USA,1 while other pathologies{\textemdash}including stroke, arrhythmias, heart valve diseases, cardiomyopathies, aneurysms, heart failure, and congenital defects{\textemdash}are also very debilitating. According to recent data, the EU expenditure for CVDs is \~{}210 billion EUR per year, while the annual direct and indirect CVD-related costs in the USA were recently estimated at 407.3 billion USD.1 It is evident therefore that CVDs constitute a huge societal problem and a colossal burden for healthcare systems.},
  year = {2024},
  journal = {Cardiovascular Research},
  pages = {cvae080},
  month = {2024-03-08},
  issn = {0008-6363},
  url = {https://doi.org/10.1093/cvr/cvae080},
  doi = {10.1093/cvr/cvae080},
}